Findings

What do systematic reviews say?

24 questions · 26 findings · 17 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 19.2%GRADE not reported 3 · 11.5%Very low 1 · 3.8%Low 6 · 23.1%Moderate 10 · 38.5%High 1 · 3.8%

Etanercept vs corticosteroids

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Overall adverse effects Duration of trials: 8 to 16 weeks · adults and adolescents with persistent asthma

The intervention showed no clear difference in overall adverse effects Duration of trials: 8 to 16 weeks (low certainty).

1 finding from 1 review

Addition of anti‐leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma 2017 · Cochrane Headline outcomes only
RR 0.96 [0.89, 1.03]
6 studies · 1899 participants
Low

Intervention not reported

Overall adverse effects Duration of trials: 8 to 24 weeks · adults and adolescents with persistent asthma

The intervention showed no clear difference in overall adverse effects Duration of trials: 8 to 24 weeks (moderate certainty).

1 finding from 1 review

Addition of anti‐leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma 2017 · Cochrane Headline outcomes only
RR 0.95 [0.83, 1.08]
6 studies · 1100 participants
Moderate

Intervention not reported

Overall adverse effects Duration of trials: 6 to 16 weeks · adults and adolescents with persistent asthma

The intervention showed no clear difference in overall adverse effects Duration of trials: 6 to 16 weeks (moderate certainty).

1 finding from 1 review

Addition of anti‐leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma 2017 · Cochrane Headline outcomes only
RR 1.06 [0.92, 1.22]
3 studies · 1024 participants
Moderate